Literature DB >> 32112059

The multiplex model of the genetics of Alzheimer's disease.

Rebecca Sims1, Matthew Hill1,2, Julie Williams3,4.   

Abstract

Genes play a strong role in Alzheimer's disease (AD), with late-onset AD showing heritability of 58-79% and early-onset AD showing over 90%. Genetic association provides a robust platform to build our understanding of the etiology of this complex disease. Over 50 loci are now implicated for AD, suggesting that AD is a disease of multiple components, as supported by pathway analyses (immunity, endocytosis, cholesterol transport, ubiquitination, amyloid-β and tau processing). Over 50% of late-onset AD heritability has been captured, allowing researchers to calculate the accumulation of AD genetic risk through polygenic risk scores. A polygenic risk score predicts disease with up to 90% accuracy and is an exciting tool in our research armory that could allow selection of those with high polygenic risk scores for clinical trials and precision medicine. It could also allow cellular modelling of the combined risk. Here we propose the multiplex model as a new perspective from which to understand AD. The multiplex model reflects the combination of some, or all, of these model components (genetic and environmental), in a tissue-specific manner, to trigger or sustain a disease cascade, which ultimately results in the cell and synaptic loss observed in AD.

Entities:  

Mesh:

Year:  2020        PMID: 32112059     DOI: 10.1038/s41593-020-0599-5

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  135 in total

1.  Current and future treatments for Alzheimer's disease.

Authors:  Konstantina G Yiannopoulou; Sokratis G Papageorgiou
Journal:  Ther Adv Neurol Disord       Date:  2013-01       Impact factor: 6.570

2.  Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Authors:  Rachelle S Doody; Martin Farlow; Paul S Aisen
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

Review 3.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

4.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Authors:  Lawrence S Honig; Bruno Vellas; Michael Woodward; Mercè Boada; Roger Bullock; Michael Borrie; Klaus Hager; Niels Andreasen; Elio Scarpini; Hong Liu-Seifert; Michael Case; Robert A Dean; Ann Hake; Karen Sundell; Vicki Poole Hoffmann; Christopher Carlson; Rashna Khanna; Mark Mintun; Ronald DeMattos; Katherine J Selzler; Eric Siemers
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

5.  Disease-modifying treatments for Alzheimer's disease.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

6.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.

Authors:  A Goate; M C Chartier-Harlin; M Mullan; J Brown; F Crawford; L Fidani; L Giuffra; A Haynes; N Irving; L James
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.

Authors:  E I Rogaev; R Sherrington; E A Rogaeva; G Levesque; M Ikeda; Y Liang; H Chi; C Lin; K Holman; T Tsuda
Journal:  Nature       Date:  1995-08-31       Impact factor: 49.962

Review 9.  The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.

Authors:  Roberta Ricciarelli; Ernesto Fedele
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

View more
  90 in total

1.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

Review 2.  The role of innate immunity in Alzheimer's disease.

Authors:  Hannah E Ennerfelt; John R Lukens
Journal:  Immunol Rev       Date:  2020-06-26       Impact factor: 12.988

Review 3.  Genetics of Alzheimer's disease: an East Asian perspective.

Authors:  Akinori Miyashita; Masataka Kikuchi; Norikazu Hara; Takeshi Ikeuchi
Journal:  J Hum Genet       Date:  2022-06-01       Impact factor: 3.172

4.  miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease.

Authors:  Ben Readhead; Jean-Vianney Haure-Mirande; Joel T Dudley; Michelle E Ehrlich; Diego Mastroeni; Mickael Audrain; Tomas Fanutza; Soong H Kim; Robert D Blitzer; Sam Gandy
Journal:  Acta Neuropathol       Date:  2020-07-14       Impact factor: 17.088

Review 5.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

Review 6.  Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.

Authors:  Dunhui Li; Craig Stewart McIntosh; Frank Louis Mastaglia; Steve Donald Wilton; May Thandar Aung-Htut
Journal:  Transl Neurodegener       Date:  2021-05-20       Impact factor: 8.014

Review 7.  Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies.

Authors:  Dapinder Kaur; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Simona Bungau
Journal:  Neurochem Res       Date:  2021-08-06       Impact factor: 3.996

Review 8.  Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

9.  Mendelian randomization integrating GWAS and mQTL data identified novel pleiotropic DNA methylation loci for neuropathology of Alzheimer's disease.

Authors:  Di Liu; Youxin Wang; Huiquan Jing; Qun Meng; Jingyun Yang
Journal:  Neurobiol Aging       Date:  2020-10-01       Impact factor: 4.673

10.  CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia.

Authors:  Chritica Lodder; Isabelle Scheyltjens; Ilie Cosmin Stancu; Kiavash Movahedi; Ilse Dewachter; Pablo Botella Lucena; Manuel Gutiérrez de Ravé; Sarah Vanherle; Tim Vanmierlo; Niels Cremers; Hannah Vanrusselt; Bert Brône; Bernard Hanseeuw; Jean-Noël Octave; Astrid Bottelbergs
Journal:  Acta Neuropathol Commun       Date:  2021-06-08       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.